Loading
Tectonic Therapeutic, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by REICIN ALISE, was filed 12 Feb 2026.
Tectonic Therapeutic, Inc.: what insiders have been doing
Tectonic Therapeutic, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). In the past year (23 October 2025 to 23 October 2026), 38 filings came from 7 insiders.
Both sides are active: 2 purchases worth €153k and 9 sales worth €528k, from 2 insiders and 2 insiders respectively. Netting one side against the other leaves €375k of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Ruddy Marcella K. filed the largest sale, €258k, on 9 March 2026. The buyers include 1 finance chief and 1 chief executive.
For context, the typical company on the same exchange (median of 3,167 companies) published 24 filings over the same period, against 38 filings here. Over the whole record (from 2018), the tally stands at 26 purchases and 21 sales. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -74.2 m USD.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 12 February 2026, 253 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
144
Thresholds
n/a
Buy Volume
€74M
26 ops. · all time
Sell Volume
€11M
21 ops. · all time
Who traded when
BuySaleSpringer Timothy A12 buys
Peter McNamara7 sales
Daniel Lochner2 buys
Marcella K. Ruddy2 sales
Alise Reicin1 buy
Mcguire Terrance1 sale
Since the insiders bought
- +33.8%Entry US$22.28 · Close at T+90 US$29.80
- +26.9%Entry US$22.71 · Close at T+90 US$28.81
- +67.7%Entry US$17.87 · Close at T+365 US$29.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Tectonic Therapeutic, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$71.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$21.84
Analyst consensus
9 analystsStrong buy
US$26.00Target US$71.00(+225%)US$93.00
Income statement
EBITDA-US$71.5M
Net income-US$74.2M0.0% margin
Valuation
PER (forward)-4.6x
P/Book1.9x
Beta0.38
Balance sheet & cash
Market capUS$427M
Total debtUS$1.3M
Free Cash Flow-US$60.3M
Debt / Equity2%
Profitability & ownership
ROE-33.8%
ROA-22.3%
% insiders37.6%
% institutions72.0%
Last declaration on 2 October 2026
Declarations144 total
520 shares@ US$23.670.0026% mcap2.7% of flowCommon StockSEC:0001791187-26-000010:0
444 shares@ US$23.670.0023% mcap7.7% of flowCommon StockSEC:0002023255-26-000012:0
536 shares@ US$23.040.0027% mcap9.1% of flowCommon StockSEC:0002023255-26-000012:1
525 shares@ US$23.670.0027% mcap3.2% of flowCommon StockSEC:0002023849-26-000014:0
1,545 shares@ US$23.670.0079% mcap16.6% of flowCommon StockSEC:0001757533-26-000016:0
411 shares@ US$23.670.0021% mcap14.2% of flowCommon StockSEC:0002023175-26-000009:0
493 shares@ US$23.340.0025% mcap67.0% of flowCommonSEC144:0001950047-26-009887
7,513 shares@ US$36.83190.055% mcap42.0% of flowCommonSEC144:0001950047-26-008795
43 shares@ US$14.710.0001% mcap0.5% of flowCommon StockSEC:0002023255-26-000009:0
43 shares@ US$36.520.0003% mcap1.3% of flowCommon StockSEC:0002023255-26-000009:1
10,200 shares@ US$37.61480.076% mcap58.0% of flowCommonSEC144:0001950047-26-008563
43 shares@ US$14.710.0001% mcap0.5% of flowCommon StockSEC:0002023255-26-000007:0
43 shares@ US$35.000.0003% mcap1.3% of flowCommon StockSEC:0002023255-26-000007:1
129 shares@ US$31.870.0009% mcap100.0% of flowCommonSEC144:0001950047-26-008032
172 shares@ US$33.090.0012% mcap100.0% of flowCommonSEC144:0001950047-26-006668
1,000 shares@ US$31.058.2% of flowCommon StockSEC:0002023849-26-000006:0
215 shares@ US$14.710.8% of flowCommon StockSEC:0002023255-26-000005:1
6,047 shares@ US$30.0048.7% of flowCommon StockSEC:0002023255-26-000005:2
215 shares@ US$35.002.0% of flowCommon StockSEC:0002023255-26-000005:3
10,000 shares@ US$30.0079.3% of flowCommon StockSEC:0002023849-26-000004:0
2,500 shares@ US$2.385.1% of flowCommon StockSEC:0002023255-26-000005:0
23,000 shares0Common StockSEC:0002023255-26-000004:1
1,650 shares@ US$25.0011.1% of flowCommon StockSEC:0002023255-26-000004:2
26,500 shares0Common StockSEC:0001791187-26-000005:0
1,649 shares@ US$22.0631.1% of flowCommon StockSEC:0002023255-26-000004:0
25 of 144 declarations
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. is a U.S.-based clinical-stage biotechnology company listed on the NASDAQ market in the United States. For investors, the company represents a classic development-stage biotech story: the investment case is driven by scientific platform quality, clinical execution, and future data readouts rather than current product sales. Tectonic is headquartered in Watertown, Massachusetts, within the Boston biotech cluster, which gives it access to a dense ecosystem of research talent, clinical expertise, and outsourcing partners. The company describes its core focus as the discovery and development of therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs). ([investors.tectonictx.com](https://investors.tectonictx.com/news-releases/news-release-details/tectonic-therapeutic-announces-first-quarter-2026-financial/))
Tectonic does not yet have any approved products and has never generated product revenue, underscoring its status as a clinical development company. Its lead asset, TX45, is a long-acting Fc-relaxin fusion protein being advanced for cardiopulmonary and cardiovascular indications with significant unmet need, including Group 2 pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF). Management has highlighted ongoing Phase 2 work, with topline data expected in 2026, and has also initiated a second Phase 2 trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company advanced TX2100, a potential treatment for hereditary hemorrhagic telangiectasia (HHT), dosing the first healthy volunteer in a Phase 1a study in 2026. ([investors.tectonictx.com](https://investors.tectonictx.com/news-releases/news-release-details/tectonic-therapeutic-announces-fourth-quarter-and-full-year-2025/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Tectonic is pursuing a differentiated GPCR biology strategy in diseases where therapeutic options remain limited or nonexistent. That can create meaningful upside if clinical efficacy is validated, especially because biologics targeting these pathways may offer novel mechanisms of action. At the same time, the company faces the usual biotech risks: binary clinical outcomes, regulatory uncertainty, capital intensity, and dilution risk. Its latest filings show substantial cash resources, with approximately $253.8 million in cash and cash equivalents as of December 31, 2025, which supports the funding runway while programs advance through the clinic. ([investors.tectonictx.com](https://investors.tectonictx.com/static-files/a34b5b12-4206-4a26-8c9a-669c98640eb5))
Recent highlights have been important for the equity story. Tectonic reported positive interim and topline clinical data for TX45 across 2025, expanded its pipeline into a second clinical program, and completed a private placement in 2025 that strengthened the balance sheet. In early 2026, the company also appointed François Nader, M.D., as Chair of the Board, adding experienced biopharmaceutical leadership as the pipeline matures. Overall, Tectonic remains a speculative but potentially differentiated NASDAQ-listed U.S. biotech, best followed through clinical milestones, cash burn, and the pace of platform validation. ([investors.tectonictx.com](https://investors.tectonictx.com/news-releases/news-release-details/tectonic-therapeutic-announces-fourth-quarter-and-full-year-2025/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
